
News|Articles|December 1, 2023
AAO 2023: Luminopia, first FDA-approved digital therapeutic for amblyopia
Author(s)David Hutton, Sheryl Stevenson
Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.
Advertisement
Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
How AI is reshaping ophthalmology in 2025 and beyond
2
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases
3
8 things to know about aflibercept 8 mg for retinal vascular disease
4
AI in ophthalmology research: Ethical implications for medical students
5












































